The U.S. Department of Health and Human Services (HHS) is re-evaluating its stance on fluoride in drinking water by reconvening the Community Preventive Services Task Force, an independent panel of health experts. This move follows Health Secretary Robert F. Kennedy Jr.’s recent statement in Salt Lake City, indicating plans to halt the Centers for Disease Control and Prevention’s recommendation for community water fluoridation.
Fluoride, commonly added to public water supplies to prevent tooth decay, has been a controversial topic for decades. While the American Dental Association continues to support fluoridation as an effective dental health measure, concerns about potential health risks have gained traction.
The Environmental Protection Agency (EPA) will also review new scientific data on fluoride’s health effects. EPA Administrator Lee Zeldin confirmed that this effort is in collaboration with HHS, with the goal of re-evaluating the agency’s current enforceable fluoride limit of 4.0 milligrams per liter (mg/L). Currently, the U.S. Public Health Service recommends maintaining levels below 0.7 mg/L. Studies show that exposure above 1.5 mg/L can increase risks of bone fractures, thyroid dysfunction, and neurological damage.
In a landmark move, Utah became the first state to ban fluoride in public water systems after Governor Spencer Cox signed new legislation last month. The decision faced strong opposition from health experts and organizations, including the American Dental Association.
As of 2022, about 63% of Americans receive fluoridated water through their municipal systems. A 2024 federal court ruling ordered the EPA to tighten its standards, citing unacceptable health risks to children under current fluoride levels. While Kennedy claims links between fluoride and conditions like cancer, his statements remain unsubstantiated by definitive scientific evidence.


Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Trump Allegedly Sought Airport, Penn Station Renaming in Exchange for Hudson River Tunnel Funding
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Nighttime Shelling Causes Serious Damage in Russia’s Belgorod Region Near Ukraine Border
Pentagon Ends Military Education Programs With Harvard University
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 



